Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U)

Abstract

The results suggest that a high serum sIL-2R level predicts a poor prognosis in PTCL-U.

Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma

“…It has long been recognized that sIL-2R levels predicted inferior outcomes in CTCL [26,27] and studies of sIL-2R levels in TCL have also been consistent with our findings. sIL-2R elevations were predictive of an inferior outcome in a study of 36 AITL patients [28] and in a separate study of 30 patients with PTCL-NOS [29]. In a recent review of cytokine signaling in CTCL [30], the importance of IL-2-related cytokines and signaling through the JAK-STAT pathway was noted.…”

Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens

“…Therefore, activated T cells, B cells, and parts of lymphoid malignancies display elevated levels of sIL-2R. Except for DLBCL, increased serum sIL-2R levels have been found in patients with lymphoblastic leukemia [9], Hodgkin's disease [10], B chronic lymphocytic leukemia [11], adult T cell leukemia [12], and peripheral T cell lymphoma unspecified [13].…”

Clinical Relevance of Elevated Levels of Serum Soluble Interleukin-2 Receptor alpha (sIL-2Rα) in Patients with Non-Hodgkin’s Lymphoma

“…or diffuse large B-cell lymphoma at the time of diagnosis, and a high level of this cytokine receptor could be a prognostic factor, which could aid in predicting the outcome of these diseases in patients [8,9,11]. Others have suggested using serum sIL-2Ra levels to monitor the therapeutic response in anaplastic large cell lymphoma or malignant lymphoma [2,10,12].…”

“…Some investigators have suggested that the serum sIL-2Ra level may be a prognostic factor for selecting appropriate treatment of NHL and for determining the clinical outcome in aggressive NHL [8][9][10][11] .983). The measurement range was from 0 to 16,500 U/mL, and the detection limit was 10 U/mL.…”

“…The measurement range was from 0 to 16,500 U/mL, and the detection limit was 10 U/mL. The serum sIL-2Ra level was considered either high or low by comparing it with the median measurement level of 2,000 U/mL, as reported elsewhere [8,11]. The differences between groups in terms of median values were tested using the nonparametric Mann-Whitney U-test.…”